104 related articles for article (PubMed ID: 26058984)
21. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
[TBL] [Abstract][Full Text] [Related]
22. Comparing the alpha-galactosidase A biochemical properties from healthy individuals and Fabry disease patients.
Daitx VV; Mezzalira J; Moraes Vda C; Breier AC; Cé J; Coelho JC
Clin Chim Acta; 2015 May; 445():60-4. PubMed ID: 25804996
[TBL] [Abstract][Full Text] [Related]
23. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.
Ohashi T; Iizuka S; Ida H; Eto Y
Mol Genet Metab; 2008 Jul; 94(3):313-8. PubMed ID: 18456533
[TBL] [Abstract][Full Text] [Related]
24. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
25. Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.
Üçeyler N; Schröter N; Kafke W; Kramer D; Wanner C; Weidemann F; Sommer C
PLoS One; 2016; 11(11):e0166484. PubMed ID: 27851774
[TBL] [Abstract][Full Text] [Related]
26. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes.
Jehn U; Bayraktar S; Pollmann S; Van Marck V; Weide T; Pavenstädt H; Brand E; Lenders M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768768
[TBL] [Abstract][Full Text] [Related]
27. Case study on the pathophysiology of Fabry disease: abnormalities of cellular membranes can be reversed by substrate reduction
Brogden G; Shammas H; Maalouf K; Naim SL; Wetzel G; Amiri M; von Köckritz-Blickwede M; Das AM; Naim HY
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28351893
[TBL] [Abstract][Full Text] [Related]
28. Estimation and comparison of lysosomal and cytoplasmic pH of human fibroblasts from healthy donors and patients with lysosomal storage diseases.
Ivleva TS; Ogloblina TA; Litinskaya LL; Wiederschain GYa
Biomed Sci; 1991; 2(4):398-402. PubMed ID: 1797144
[TBL] [Abstract][Full Text] [Related]
29. Electron microscopic observations on cultured fibroblasts from Fabry heterozygotes and hemizygotes.
Wandall A; Hasholt L; Sørensen SA
Ultrastruct Pathol; 1982; 3(1):51-8. PubMed ID: 6280349
[TBL] [Abstract][Full Text] [Related]
30. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
[TBL] [Abstract][Full Text] [Related]
31. Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings.
Cigna D; D'Anna C; Zizzo C; Francofonte D; Sorrentino I; Colomba P; Albeggiani G; Armini A; Bianchi L; Bini L; Duro G
Mol Biosyst; 2013 Jun; 9(6):1162-8. PubMed ID: 23385635
[TBL] [Abstract][Full Text] [Related]
32. L-Acetylcarnitine causes analgesia in mice modeling Fabry disease by up-regulating type-2 metabotropic glutamate receptors.
Formaggio F; Rimondini R; Delprete C; Scalia L; Merlo Pich E; Liguori R; Nicoletti F; Caprini M
Mol Pain; 2022; 18():17448069221087033. PubMed ID: 35255745
[TBL] [Abstract][Full Text] [Related]
33. Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease.
Yokoi T; Kobayashi H; Shimada Y; Eto Y; Ishige N; Kitagawa T; Otsu M; Nakauchi H; Ida H; Ohashi T
J Gene Med; 2011 May; 13(5):262-8. PubMed ID: 21520359
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor (VEGF-a) in Fabry disease: association with cutaneous and systemic manifestations with vascular involvement.
Zampetti A; Gnarra M; Borsini W; Giurdanella F; Antuzzi D; Piras A; Smaldone C; Pieroni M; Cadeddu C; de Waure C; Feliciani C
Cytokine; 2013 Mar; 61(3):933-9. PubMed ID: 23332617
[TBL] [Abstract][Full Text] [Related]
35. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
[TBL] [Abstract][Full Text] [Related]
36. [A pH increase in human fibroblast lysosomes during accumulation of non-hydrolysable compounds].
Ivleva TS; Ogloblina TA; Litinskaia LL; Vidershaĭn GIa
Biokhimiia; 1990 Jan; 55(1):95-101. PubMed ID: 2111716
[TBL] [Abstract][Full Text] [Related]
37. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
38. Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease.
Chiba Y; Sakuraba H; Kotani M; Kase R; Kobayashi K; Takeuchi M; Ogasawara S; Maruyama Y; Nakajima T; Takaoka Y; Jigami Y
Glycobiology; 2002 Dec; 12(12):821-8. PubMed ID: 12499404
[TBL] [Abstract][Full Text] [Related]
39. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
[TBL] [Abstract][Full Text] [Related]
40. Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase A produced in Pichia pastoris.
Chen Y; Jin M; Egborge T; Coppola G; Andre J; Calhoun DH
Protein Expr Purif; 2000 Dec; 20(3):472-84. PubMed ID: 11087687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
